Atrial Fibrillation Systems Market Analysis

Global Atrial Fibrillation Market Overview

Atrial Fibrillation Market Size was valued at USD 1.69 billion in 2023. The atrial fibrillation market industry is projected to grow from USD 1.91 Billion in 2024 to USD 3.6 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.24% during the forecast period (2024 - 2032). 

Rising prevalence of atrial fibrillation and increasing approval of products are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The most prevalent arrhythmia, atrial fibrillation, is brought on by irregular electrical impulses that reach the heart's upper chambers (atria). One of the most frequent heart rhythm disorders is atrial fibrillation (AF). The consequence is a quick and erratic rhythm. 100 to 175 beats a minute are possible heart rates caused by atrial fibrillation. Atrial fibrillation causes confusion, fatigue, dizziness, and fainting. 

The general healthcare system regards this condition's treatment as a strategically important issue because it is a potentially fatal disease and costly to treat. One major factor anticipated to propel the international atrial fibrillation market during the forecast period is the rise in the number of elderly people worldwide. Additionally, the growing senior population worldwide is fueling market expansion, as the risk of atrial fibrillation is higher in this group of people.

By meeting the unmet medical needs in the atrial fibrillation area, promising outcomes from clinical trials, including combination pharmacological therapy, are projected to propel the worldwide atrial fibrillation market. Businesses are conducting more of these trials to offer patients with atrial fibrillation a better course of treatment. A rise in the prevalence of atrial fibrillation in the older population, technological advancements, and an increasing demand for catheter ablation as a cardiac arrhythmia therapy are driving the growth of the atrial fibrillation market. 

The lack of skilled specialists and unfavorable preference for pharmacological therapies (drugs) over AF therapeutic devices are predicted to hinder the atrial fibrillation business. A typical and prospective atrial fibrillation treatment strategy is combined pharmacological therapy.

The combined pharmaceutical therapy showed promising results in clinical trials and would help individuals with atrial fibrillation get the medical care they require. This aspect is anticipated to impact the atrial fibrillation market internationally. Additionally, studies using an animal model to study the combined therapy produced effective and favorable anti-arrhythmic outcomes. When medication is ineffective, catheter ablation treats abnormal heart rhythms. It is a minimally invasive, low-risk approach for treating cardiac arrhythmias. The catheter ablation device also involves the removal of damaged cardiac tissues that are the source of erratic heartbeats.

A new method of detecting people at risk of atrial fibrillation, which increases the likelihood of suffering from a transient ischemic attack (TIA) and strokes by up to five times, has been discovered by UK researchers. The University of East Anglia researchers identified four distinct indicators potentially identifying patients who would develop atrial fibrillation. These include advanced age, elevated diastolic blood pressure, and issues with the upper left chamber of the heart's coordination and functionality. The researchers developed a simple tool that practitioners may use to quickly identify patients at high risk, which will aid in diagnosing and treating more patients and lower their risk of future strokes.

Positive Phase 2 data from November 2023, as reported today by Milestone Pharmaceuticals Inc., indicate that etripamil nasal spray exhibited prompt and statistically significant reduction in ventricular rate and enhanced symptom relief in patients diagnosed with atrial fibrillation with rapid ventricular rate (AFib-RVR) when compared to a placebo. 

The safety and tolerability results obtained from the 56 patients comprising the safety population are similar to those documented in Milestone's Phase 3 paroxysmal supraventricular tachycardia (PSVT) program, despite the latter's considerably larger scope. The results were disclosed in conjunction with their Featured Science presentation at the Scientific Sessions 2023 of the American Heart Association (AHA) and publication in Circulation: Arrhythmia and Electrophysiology. These results support the development of additional self-administered etripamil for the treatment of AFib-RVR.

In November 2023, Anthos Therapeutics, Inc., a clinical stage company founded by Blackstone Life Sciences with the aim of developing innovative therapies for cardiovascular diseases, disclosed during a Late-Breaking session of the American Heart Association (AHA) meeting that abelacimab demonstrated a significantly decreased incidence of bleeding events across all primary and secondary endpoints in comparison to a direct-oral anticoagulant (DOAC), the prevailing treatment option. 

Anthos Therapeutics has commenced an extension study with the objective of assisting patients in their transition from rivaroxaban to abelacimab, with the intention of leveraging the improved hemorrhage profile of the latter. The goal of anticoagulation therapy is to promote hemostasis maintenance and minimize thrombosis prevention or healing. Although currently available anticoagulants have demonstrated effectiveness in preventing strokes in patients with atrial fibrillation, the risk of hemorrhage remains a significant concern.

Atrial Fibrillation Market Trends

• Rising incidence rate of atrial fibrillation due to high prevalence of hypertension and obesity to boost market growth

The primary causes of cardiovascular diseases, especially atrial fibrillation, are usually high blood pressure and obesity. The Framingham Heart Study found that obesity raised the chance of paroxysmal atrial fibrillation developing to persistent atrial fibrillation by 45% to 50% and that hypertension was linked to 14% of atrial fibrillation risks. Due to socioeconomic factors including dietary and other habits brought on by a person's lifestyle, the prevalence of these diseases is increasing (excessive alcohol consumption and smoking). According to WHO assumptions, 35% of people aged 20 years and over were overweight. Since 1980, the prevalence of obesity has nearly doubled worldwide, and it is predicted to rise quickly in the coming years. 

In 2008, there were 1 billion people worldwide who had hypertension. According to the WHO, there were 40% of low, middle, and upper middle-income nations and 35% of high-income countries with hypertension prevalence in 2008. The worldwide atrial fibrillation market CAGR is anticipated to grow throughout the forecast period due to the high and rising prevalence of these disorders.

However, from over projected period, rising atrial fibrillation rates are anticipated to fuel the expansion of the worldwide atrial fibrillation market. For instance, data from the Centers for Disease Control and Prevention (CDC) published in July 2022 indicated that more than 454,000 hospitalizations in the United States each year have atrial fibrillation as the major diagnosis. Each year, the disease causes roughly 158,000 deaths in the United States.

Moreover, the combination pharmaceutical therapy is a model and promising atrial fibrillation treatment option. In clinical trials, the combined pharmacological therapy demonstrated positive outcomes and would assist meet the unmet medical needs of patients with atrial fibrillation. The atrial fibrillation market is expected to be driven by this factor globally. Additionally, research on the combined therapy in an animal model revealed positive and effective anti-arrhythmic results. 

The Boston Atrial Fibrillation Symposium have seen the introduction of the clinical trials intended to evaluate the effectiveness of a combined therapy using Multaq and Ranexa. Around 150 individuals with non-permanent atrial fibrillation and pacemaker implants were enrolled in the HARMONY clinical trial. Preclinical data from this investigation indicate that this combination therapy, especially in terms of safety and efficacy, is well positioned in the existing atrial fibrillation market revenue.

Atrial Fibrillation Market Segment Insights

Atrial Fibrillation Treatment Insights

The atrial fibrillation market segmentation, based on treatment, includes medications, non-surgical procedures, surgical procedures. The surgical procedures atrial fibrillation segment held the majority share in 2022 in the atrial fibrillation market revenue. This is primarily owing to the increased use of cardiac monitoring technology during atrial fibrillation treatment. The number of patients with arrhythmia or a condition with an irregular heartbeat has increased, which has increased demand for cardiac monitors.

Atrial Fibrillation End User Insights

The atrial fibrillation market segmentation, based on end-user, includes hospitals, electrophysiology labs, ambulatory surgical centers. The hospitals segment dominated the market in 2022. This is due to the increasing use of laser and radio frequency ablation technologies also rising investment globally for the development hospital infrastructure by public and private players is anticipated to support the market growth.

Figure 2: Atrial Fibrillation Market, by End-User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

News:

Following Boston Scientific's announcement of encouraging findings from a clinical study for their system to treat people with atrial fibrillation (AF), the medical device manufacturer's stock had the best performance in the S&P 500. Rather than the more conventional thermal approach, the Farapulse Pulsed Field Ablation (PFA) removes cardiac tissue that is the cause of irregular heartbeats. Six hundred seven paroxysmal AF patients who had received a minimum of one anti-arrhythmic medication ineffectively in the past participated in the trial. The Farapulse met the major efficacy and safety criteria, according to data that demonstrated comparable performance to standard-of-care medicines.

Atrial Fibrillation Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Atrial Fibrillation market accounted for USD 0.68 billion in 2022 and is expected to exhibit a significant CAGR 45.80% growth during the study period. The main factor driving the growth of the atrial fibrillation market is the high adoption of technologically improved devices for atrial fibrillation in North American nations. 

Moreover, one of the biggest problems facing healthcare systems is the sharp rise in cardiac disorders among the ageing population. As a result, in order to address this issue, numerous new products are authorized and introduced in North American countries, which further fuels the expansion of the atrial fibrillation market.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Atrial Fibrillation MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe atrial fibrillation market accounts for the second-largest market share due to the enormous patient population, expanding medical tourism, and considerable attention given by international market participants to developing European nations like Germany and the United Kingdom. Further, the Germany atrial fibrillation market held the largest market share, and the United Kingdom atrial fibrillation market was the fastest growing market in the European region

The Asia-Pacific Atrial Fibrillation Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to government initiatives to support healthcare and strong economic growth. Moreover, the Asia Pacific atrial fibrillation market is anticipated to develop as a result of rising purchasing power, rising consumer awareness of health issues, and improved disease management. Moreover, China atrial fibrillation market held the largest market share, and the India atrial fibrillation market was the fastest growing market in the Asia-Pacific region

Atrial Fibrillation Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the atrial fibrillation market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the atrial fibrillation industry must offer cost-effective products and services to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the atrial fibrillation industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, atrial fibrillation industry has provided transparency and reduced disruptions in supply chain. The atrial fibrillation market major player such as Johnson & Johnson Services Inc, Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure Inc., CardioFocus, Osypka AG and others are working to expand the market demand by investing in research and development activities.

Abbott Laboratories is an American Conglomerate which was established in the year 1888 and headquartered in Chicago, Illinois, United States. It works under diverse range of portfolio, ranging from nutritional, diagnostics to pharmaceuticals and vascular products. Wherein the Vascular is the top selling segment, which ranges from coronary to endovascular, vessel closure and heart devices. The company has an employee base of 18000+ over the world and has established its name with a well-maintained goodwill in the market. There are currently 414+ subsidiaries running under its name and serving its customers over the world. 

For instance, Aug. 2020, TactiFlex PAF IDE ablation catheter is used to treat patients with paroxysmal atrial fibrillation, an irregular heartbeat, according to Abbott Laboratories, a producer of healthcare medical devices and products. For patients with atrial fibrillation (AFib) symptoms that cannot be managed by medication, it has sensors enabled.

Also, CardioFocus, Inc. was established in year 1990 and it headquarters is in Marlborough, Massachusetts. The company is a medical device inventor and producer dedicated to advancing embolization treatment for cardiovascular disorders such as atrial fibrillation (AFib), a most common heart arrhythmia. More than 10,000 patients in the US, Europe, and Japan have been successfully treated with the company's FDA-approved HeartLight Endoscopic Ablation System. 

A new benchmark for AFib ablation has been set by the revolutionary HeartLight System, which combines direct vision with titratable laser energy. For instance, in May 2020, CardioFocus, Inc. announced that it has obtained the U.S. Food & Drug administration approval for the next-generation HearLight X3 Endoscopic Ablation System. The system can be utilized to treat paroxysmal symptomatic atrial fibrillation that is drug-refractory and recurrent.

Key Companies in the atrial fibrillation market includes

• Johnson & Johnson Services Inc.


• Abbott


• Medtronic Plc


• Boston Scientific Corporation


• MicroPort Scientific Corporation


• Biotronik SE & Co. KG


• Koninklijke Philips N.V.


• AtriCure Inc.


• CardioFocus


• Osypka AG

Atrial Fibrillation Industry Developments

Jan. 2022: AliveCor, Inc. and Voluntis, a pioneer in digital medicines and Aptar Pharma firm, has collaborated to advance atrial fibrillation management for cancer patients.

Atrial Fibrillation Market Segmentation

Atrial Fibrillation Type Outlook

• Paroxysmal atrial fibrillation


• Persistent atrial fibrillation


• Permanent atrial fibrillation

Atrial Fibrillation Treatment Outlook

• Medications


• Non-surgical procedures


• Surgical procedures

Atrial Fibrillation End User Outlook

• Hospitals


• Electrophysiology Labs


• Ambulatory Surgical Centers

Atrial Fibrillation Regional Outlook

• North America


• US


• Canada


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America